NanoGenics is a leading RNA therapeutics company looking to address major unmet need in ophthalmology and oncology. Our lead product, ECP-105, is our novel glaucoma therapy. We expect to have it in clinic in 2025, followed closely by several other promising medicines.

The precision delivery of our products is accomplished by harnessing our unique proprietary delivery technology, LipTide.

Please contact us to learn more about how we are taking our products all the way to the clinic door.